CVE-2026-59666: Cross-Site Scripting Vulnerability
Source GCVE Database
Not known to be exploited · CVSS 4.8 Medium : upgrade to Abril patch "20260402" when convenient.
Data as of 15 Nov 2026, 20:25 UTC
- EPSS
- 0.2% chance of exploitation in 30 days – higher than 21% of CVEsExploit Prediction Scoring System: the likelihood attackers will use this flaw soon.
- Patch
- Available – fixed in Abril patch "20260402"
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:A/VC:L/VI:L/VA:N/SC:N/SI:N/SA:NExploitation evidence
Disclosed: evidence found.
CVE published 2 Oct 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 15 Nov 2026.
What to do
Upgrade Repasat application to Abril patch "20260402".
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| RepasatRepasat application | Affected
| Fixed in
|
AI-suggested
If you cannot patch yet, consider applying input validation or output encoding on the 'nomOrigen' parameter to mitigate XSS risks. Monitor vendor communications for official patches or updates.
Description
A Cross-Site Scripting (XSS) vulnerability exists in the Repasat application affecting the 'nomOrigen' parameter at the '/es/origins/store' endpoint. This vulnerability allows an attacker to execute arbitrary code in a victim's browser by tricking the user. The vulnerability is classified as medium severity. There are no known exploits in the wild.